378 related articles for article (PubMed ID: 21700509)
21. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review.
Gerullis H; Ecke T; Eimer C; Wishahi M; Otto T
Anticancer Drugs; 2011 Jan; 22(1):9-17. PubMed ID: 20948429
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
24. Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).
Passalacqua R; Lazzarelli S; Donini M; Montironi R; Tambaro R; De Giorgi U; Pignata S; Palumbo R; Ceresoli GL; Del Conte G; Tonini G; Morelli F; Nolè F; Panni S; Rondini E; Guida A; Zucali PA; Doni L; Iezzi E; Caminiti C
BMC Cancer; 2017 Jul; 17(1):493. PubMed ID: 28724419
[TBL] [Abstract][Full Text] [Related]
25. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
[TBL] [Abstract][Full Text] [Related]
26. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy of metastatic urothelial carcinoma].
Kihara K; Sakuramoto T; Washizuka M; Kawai T; Ogawa M
Gan To Kagaku Ryoho; 1982 Nov; 9(11):2046-7. PubMed ID: 6892194
[TBL] [Abstract][Full Text] [Related]
28. Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?
Mertens LS; Meijer RP; Kerst JM; Bergman AM; van Tinteren H; van Rhijn BW; Horenblas S
J Urol; 2012 Oct; 188(4):1108-13. PubMed ID: 22901581
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
Castellano DE; Bellmunt J; Maroto JP; Font-Pous A; Morales-Barrera R; Ghanem I; Suarez C; Martín Lorente C; Etxaniz O; Capdevila L; Coronado C; Alfaro V; Siguero M; Fernández-Teruel C; Carles J
Cancer Chemother Pharmacol; 2014 Apr; 73(4):857-67. PubMed ID: 24570330
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Apolo AB; Nadal R; Tomita Y; Davarpanah NN; Cordes LM; Steinberg SM; Cao L; Parnes HL; Costello R; Merino MJ; Folio LR; Lindenberg L; Raffeld M; Lin J; Lee MJ; Lee S; Alarcon SV; Yuno A; Dawson NA; Allette K; Roy A; De Silva D; Lee MM; Sissung TM; Figg WD; Agarwal PK; Wright JJ; Ning YM; Gulley JL; Dahut WL; Bottaro DP; Trepel JB
Lancet Oncol; 2020 Aug; 21(8):1099-1109. PubMed ID: 32645282
[TBL] [Abstract][Full Text] [Related]
31. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
[TBL] [Abstract][Full Text] [Related]
33. Satraplatin for the therapy of castration-resistant prostate cancer.
Sonpavde G; Sternberg CN
Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
[TBL] [Abstract][Full Text] [Related]
34. Satraplatin: leading the new generation of oral platinum agents.
Bhargava A; Vaishampayan UN
Expert Opin Investig Drugs; 2009 Nov; 18(11):1787-97. PubMed ID: 19888874
[TBL] [Abstract][Full Text] [Related]
35. Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Beer TM; Goldman B; Nichols CR; Petrylak DP; Agarwal M; Ryan CW; Crawford ED;
Clin Genitourin Cancer; 2008 Mar; 6(1):36-9. PubMed ID: 18501081
[TBL] [Abstract][Full Text] [Related]
36. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
[TBL] [Abstract][Full Text] [Related]
37. Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.
Hong JY; Choi MK; Uhm JE; Park MJ; Lee J; Park SH; Park JO; Kim WS; Kang WK; Lee HM; Choi HY; Lim H
Med Oncol; 2009; 26(2):186-92. PubMed ID: 18988001
[TBL] [Abstract][Full Text] [Related]
38. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
Lassiter LK; Tummala MK; Hussain MH; Stadler WM; Petrylak DP; Carducci MA
Clin Genitourin Cancer; 2008 Mar; 6(1):31-5. PubMed ID: 18501080
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
[TBL] [Abstract][Full Text] [Related]
40. Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.
Sonpavde G; Pond GR; Di Lorenzo G; Buonerba C; Rozzi A; Lanzetta G; Necchi A; Giannatempo P; Raggi D; Matsumoto K; Choueiri TK; Mullane S; Niegisch G; Albers P; Lee JL; Kitamura H; Kume H; Bellmunt J
Clin Genitourin Cancer; 2016 Dec; 14(6):494-498. PubMed ID: 27262369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
